
Page 1 of 4

Making Cancer History*

THE UNIVERSITY OF TEXAS

MDAnderson Cancer Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.




Making Cancer History*

THE UNIVERSITY OF TEXAS

MD Anderson Cancer Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



NED = no evidence of disease

CMP = complete metabolic panel

¹See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

² Includes breast, cervical (if appropriate), colorectal, liver, lung, pancreatic, prostate, and skin cancer screening

³Based on Center for Disease Control and Prevention (CDC) guidelines. For COVID information, see CDC COVID vaccination guidelines.

Page 2 of 4

Cancer Center Making Cancer History*

THE UNIVERSITY OF TEXAS

MDAndersor

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- American Cancer Society. (2022). *American Cancer Society guidelines for the early detection of cancer*. Retrieved from http://www.cancer.org/Healthy/FindCancerEarly/ CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer
- Bellizzi, K. M., Rowland, J. H., Arora, N. K., Hamilton, A. S., Miller, M. F., & Aziz, N. M. (2009). Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27(6), 960-966. doi:10.1200/JCO.2008.17.5026
- Centers for Disease Control and Prevention. (2022). *Recommended immunization schedule for adults aged 19 years or older, United States, 2022*. Retrieved from https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html
- Ewer, M. S., & Ewer, S. M. (2009). Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data. *Journal of Clinical Oncology*, 27(36), 6073-6075. doi:10.1200/JCO.2009.25.5091
- Ewer, M. S., Von Hoff, D. D., & Benjamin, R. S. (2011). A historical perspective of anthracycline cardiotoxicity. Heart Failure Clinics, 7(3), 363-372. doi:10.1016/j.hfc.2011.03.001
- Hibberd, P. L. & Kotton, C.N. (2022). Immunizations in adults with cancer. *UpToDate*. Retrieved November 16, 2022, from http://www.uptodate.com/contents/immunizations-in-patients-with cancer
- Kaplan, B., Kopyltsova, Y., Khokhar, A., Lam, F., & Bonagura, V. (2014). Rituximab and immune deficiency: Case series and review of the literature. *The Journal of Allergy and Clinical Immunology: In Practice, 2*(5), 594-600. doi:10.1016/j.jaip.2014.06.003
- Murthy, N., Wodi, A.P., Bernstein, H., McNally, V., Cineas, S., & Ault, K. (2022). Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2022. *Morbidity and Mortality Weekly Report February 18, 2022, 71*(7), 229-233. doi:10.15585/mmwr.mm7107a1
- Lin, T. L., Kuo, M. C., Shih, L. Y., Dunn, P., Wang, P. N., Wu, J. H., ... Lu, S. C. (2012). Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. *Annals of Hematology*, *91*(11), 1741-1745. doi:10.1007/s00277-012-1508-0
- National Comprehensive Cancer Network. (2022). Survivorship (NCCN Guideline Version 1.2022). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf
- Ng, A. K., LaCasce, A., & Travis, L. B. (2011). Long-term complications of lymphoma and its treatment. Journal of Clinical Oncology, 29(14), 1885-1892. doi:10.1200/JCO.2010.32.8427
- Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., ... Ladetto, M. (2015). Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, *26*(suppl 5), v116-v125. doi:10.1093/annonc/mdv304

Vanderbilt Cardio-Oncology Program. (2017). Know Your ABCDE's. Retrieved from http://www.cardioonc.org/2017/08/29/know-your-abcs/

Page 3 of 4

Making Cancer History®

THE UNIVERSITY OF TEXAS

MDAnderson Cancer Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Lymphoma Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Alma Rodriguez, MD (Lymphoma/Myeloma) Jason Westin, MD (Lymphoma/Myeloma)

Workgroup Members

Sairah Ahmed, MD (Lymphoma/Myeloma) Luis Fayad, MD (Lymphoma/Myeloma) Olga N. Fleckenstein, BS[•] Katherine Gilmore, MPH (Cancer Survivorship) Fredrick Hagemeister, MD (Lymphoma/Myeloma) Haleigh Mistry, MPAS, PA (Lymphoma/Myeloma) Ellen Mullen, PHD, MSN, ANP, GNP (Lymphoma/Myeloma) Hannah Warr, MSN, RN, CPHON[•]

Clinical Effectiveness Development Team

Page 4 of 4